🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Osthole ameliorates cognitive impairment in ovariectomized rats via estrogen-mediated enhancement of cholinergic function and regulation of neurotransmitter homeostasis.

PMID: 41391505 · DOI: 10.1016/j.neuropharm.2025.110806 · Neuropharmacology, 2026 · Yanman Liu, Jimei Zhang, Wenjuan Li, Qingwen Qu, Zhengxing Shan, Chunwei Liu, Ke Jiao, Xueqin Hou
📄 Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive dysfunction that is closely associated with cholinergic system damage. Estrogen deficiency is a well-established risk factor for AD in women. Osthole (OST), a phytoestrogen with mild, bidirectional regulatory properties, has been proposed as a potential estrogen replacement. This study aimed to investigate the mechanisms by which OST ameliorates cognitive impairment. Cognitive deficits were induced in female Sprague-Dawley rats by bilateral ovariectomy (OVX), and OST was subsequently administered by oral gavage. Behavioral tests revealed that OST significantly improved learning and memory and reduced anxiety-like and depression-like behaviors in OVX rats. H&E staining and Nissl staining demonstrated that OST reversed neuronal damage in the hippocampus and cortex. Western blotting, ELISA, and immunofluorescence staining indicated that OST treatment restored the estrogen-cholinergic-NGF axis: E

Confidence: 0.32 · 9 полей извлечено
Идентификация (6 полей)
Target
0.00
Alt. target
0.00
Protein family
0.00
Functional class
0.00
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
Osthole administered by oral gavage to ovariectomized rats
0.90
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
Ovariectomized female Sprague-Dawley rats
0.90
Diet/model
Ovariectomy-induced estrogen deficiency
0.90
Клиника (11 полей)
Drug
Osthole
1.00
Indication
Alzheimer's disease
0.90
Patient subgroups
Postmenopausal women with estrogen deficiency
0.80
Safety concerns
0.00
Off-target
0.00
Trial stage
Preclinical
0.90
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
Improved learning and memory, reduced anxiety-like and depression-like behaviors, reversed neuronal damage
0.90
Approved
False
0.90